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Abstract
Low serum 25-hydroxyvitamin D [25(OH)D] is common in healthy children particularly in blacks. 
However, serum 25(OH)D concentrations for optimal bone turnover in children is unknown and 
few data exist that describe effects of increasing serum 25(OH)D on bone turnover markers during 
puberty. The purpose of this study was to determine the relationships between serum 25(OH)D 
and changes in serum 25(OH)D and bone turnover in white and black pubertal adolescents. Bone 
turnover markers were measured in 318 healthy boys and girls from Georgia (34°N) and Indiana 
(40°N) who participated in a study of oral vitamin D3 supplementation (0 to 4000 IU/d). Serum 
25(OH)D, osteocalcin, bone alkaline phosphatase, and urine N-telopeptide cross-links were 
measured at baseline and 12 weeks. Relationships among baseline 25(OH)D and bone biomarkers, 
and between changes over 12 weeks were determined and tested for effects of race, sex, latitude, 
and baseline 25(OH)D. Median 25(OH)D was 27.6 ng/mL (n=318, range 10.1–46.0 ng/mL) at 
baseline and 34.5 ng/mL (n=302, range 9.7–95.1 ng/mL) at 12 weeks. Neither baseline nor change 
in 25(OH)D over 12 weeks were associated with bone turnover. The lack of association was not 
affected by race, sex, latitude, or baseline serum 25(OH)D. Serum 25(OH)D in the range of 10-46 
ng/mL appears to be sufficient for normal bone turnover in healthy black and white pubertal 
adolescents.
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1. Introduction
A high prevalence of low serum 25-hydroxyvitamin D [25(OH)D] has been reported in 
healthy children and adolescents [1-4], which has driven the concept that it is important to 
improve vitamin D status in this population. But, there are few data to support a level of 
serum 25(OH)D for optimal bone turnover in children above that which is necessary to 
prevent rickets (> 10 ng/mL). Further, American black children compared with white 
children have lower serum 25(OH)D [1-3], but generally higher bone mass and strength 
[5-7], indicating that optimal vitamin D status in blacks, at least for bone health outcomes, 
may be different from that for whites.
In the absence of functional outcomes such as bone mineral density and fracture, which 
require large sample sizes and relatively long study durations, biochemical markers of bone 
formation and bone resorption are potentially useful to gauge the influence of vitamin D 
supplementation on bone. During puberty, serum concentrations of bone turnover markers 
are high compared with adult values [8]. Cross-sectional data linking serum 25(OH)D and 
bone turnover markers in children and adolescents are conflicting. A study in adolescent 
Chinese girls [9] reported a negative association between serum 25(OH)D and markers of 
both bone formation and resorption, whereas, two studies in European children across 
pubertal stages [8, 10] reported lack of associations between serum 25(OH)D and markers of 
bone formation and resorption. Though few prospective data exist that describe the effects 
of increasing serum 25(OH)D on bone turnover markers during puberty in healthy children, 
several studies [11-13] have shown that vitamin D supplementation in children increases 
serum 25(OH)D, but has little influence on bone turnover markers. These studies, however, 
used relatively low doses of vitamin D supplementation (200 – 600 IU/d) with result that the 
magnitude of change in serum 25(OH)D may not have been great enough to elicit 
measurable changes in bone turnover. In addition, data are lacking comparing bone turnover 
markers in whites and blacks following vitamin D3 supplementation.
This study aimed to determine the baseline relationships between serum 25(OH)D and bone 
turnover markers in American black and white children who participated in a 12-week 
vitamin D study, using doses up to 4000 IU/day. Further, the study aimed to determine the 
effect of change in serum 25(OH)D over 12 weeks on corresponding change in bone 
turnover.
2. Participants and Methods
Healthy children in sexual maturation stages 2 or 3 as described by Tanner[14] were 
recruited from the community by advertisement to participate in a 12-week randomized, 
placebo-controlled trial of vitamin D3 supplementation, stratified for race (black and white), 
sex, and geographical location [U.S. states of Indiana (“northern site,” 40°N) and Georgia 
(“southern site,” 34°N)]. Sexual maturation stage [14] was determined by self-staging 
(breast stage for girls and genital stage for boys) with the assistance of a parent. Three-
hundred twenty-three pubertal boys (ages 8 to 13 years) and girls (ages 9 to 12 years) 
enrolled in the parent study (83 black girls [43 northern and 40 southern], 82 black boys [42 
northern and 40 southern], 78 white girls [38 northern and 40 southern], 80 white boys [40 
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northern and 40 southern]). All participants were enrolled during winter (October to 
January) to recruit children whose serum 25D had reached the seasonal nadir. In the parent 
study, participants were randomized to receive 0, 400, 1000, 2000, or 4000 IU/d of oral 
vitamin D3 supplements (Douglas Laboratories, Pittsburgh, PA). Vitamin D3 supplement 
doses were confirmed by an independent lab (Covance, Inc.). Compliance with 
supplementation was assessed by pill count. The study protocol was approved by the 
Institutional Review Boards of the University of Georgia, Purdue University, and Indiana 
University School of Medicine. All participants and parents/guardians provided informed 
assent and consent, respectively.
2.1 Serum and Urine Biochemistries
Fasting serum and urine samples were collected at baseline and 12 weeks and stored at 
-80°C until analysis. Each analyte was measured at a single laboratory for all participants 
and blocked such that baseline and 12-week samples for each participant were measured at 
the same time. Serum 25(OH)D (ng/mL) was measured by RIA (Diasorin, Stillwater, USA) 
in a DEQAS participant laboratory (CV 5.5 %). Bone turnover markers were measured by 
ELISA: Serum osteocalcin (OC, ng/mL) and bone alkaline phosphatase (BAP, U/L) 
(MicroVue™, Quidel Corporation, San Diego, CA; CV 8.0 % and 4.1 %, respectively), and 
urine N-telopeptide cross-links (Ntx, nM bone collagen equivalents; Osteomark®, Wampole 
Laboratories, Princeton, NJ, CV 4.6 %). Urine creatinine (mM) was measured by 
colorimetric assay using a COBAS MIRA clinical analyzer (Roche Diagnostic, Indianapolis, 
IN). Urine Ntx was corrected for urine creatinine and values reported are in nM bone 
collagen equivalents/mM creatinine.
2.2 Statistical Analyses
Statistical Analysis Software (SAS 9.2, Cary, NC) was used for statistical analyses. Seven 
outliers for urine Ntx (all > 4 SD above the mean) were excluded from the analyses. 
Transformed values for bone turnover markers were used in the statistical analyses to satisfy 
the assumption of normally distributed errors: square-root BAP, natural log OC, natural log 
Ntx. For change from baseline to 12 weeks, a natural log transformation for OC was used 
and the other variables remained in original units. Independent samples t-tests were used to 
determine race differences in baseline variables. Because the aim of the analysis was to 
determine the relationship between serum 25(OH)D and bone turnover the effect of dose of 
vitamin D supplement on serum 25(OH)D was not examined. Simple regression was used to 
determine relationships among baseline values for serum 25(OH)D, BAP, OC, and urine 
Ntx. Then, to determine if change in 25(OH)D over 12 weeks impacted bone turnover, 
simple regressions were performed among change in 25(OH)D and change in BAP, OC, and 
Ntx. Regressions were also performed by month of enrollment to investigate any intra-
seasonal variation in the relationships among variables. Multivariate regression was used to 
determine if the relationships among variables were affected by adjusting for sexual 
maturation stage, race, sex, latitude, and baseline serum 25(OH)D. The effect of race on the 
relationship between 25(OH)D and bone turnover was also investigated by repeating the 
simple regressions in whites and blacks separately. The Bonferroni method was used to 
adjust the overall significance level of α = 0.05 for multiple tests, which gave an adjusted 
significance level of α = 0.002.
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3. Results
3.1 Relationships among Baseline Variables
Baseline demographic and biochemical variables are presented for 318 participants in Table 
1. Five participants were excluded due to lack of baseline biochemical data. Median serum 
25(OH)D was 27.6 ng/mL at baseline (Figure 1A, Table 1). There were 47 participants (14.7 
%) with 25(OH)D in the insufficiency range (< 20 ng/mL) and no participants in the 
deficiency range (< 10 ng/mL). Blacks had lower 25(OH)D (p < 0.0001) and higher OC (p < 
0.0001) than whites. Baseline serum 25(OH)D was not associated with baseline serum BAP 
or urine Ntx, and there was a modest negative association with serum OC (R2 = 0.05, p < 
0.0001), which was no longer statistically significant after adjusting for race or multivariate 
adjustment for sexual maturation, race, sex, and latitude (Table 2A). The analysis of blacks 
and whites separately yielded similar results (Figures 2A-C). Relationships among baseline 
variables were not affected by month of enrollment (data not shown).
3.2 Relationships among 12-week Change
Data from 302 participants who completed the 12-week study are included in the 
prospective analysis. The range of vitamin D3 doses from 0 to 4000 units shifted median 
serum 25(OH)D at 12 weeks to 34.5 ng/mL (range 9.7 to 95.1 ng/mL; Figure 1B, Table 1) 
and produced changes in serum 25(OH)D ranging from -5.9 to +62.4 ng/mL at 12 weeks 
(Figure 1C). There were 26 (9%) participants at 12 weeks in the vitamin D insufficiency 
range (< 20 ng/mL) and 1 (<1%) in the vitamin D deficiency range (< 10 ng/mL). Mean 
change in serum 25(OH)D was higher with each increasing level of vitamin D3 dosage: 
(-3.5, +1.8, +7.6, +14.1, +31.2 ng/mL for 0, 400, 1000, 2000, 4000 IU/d, respectively, p < 
0.002 for all doses).
Similar to baseline results, 12-week serum 25(OH)D was not related to 12-week bone 
turnover markers (data not shown). Change in serum 25(OH)D was not correlated with 
change in serum BAP (R2 = 0.001, p = 0.56), serum OC (R2 = 0, p = 0.71), or urine Ntx (R2 
= 0.01, p = 0.15; Table 2B, Figures 2D-F).
Adjustment for race alone, or multivariate adjustment for sexual maturation, race, sex, 
latitude, and baseline serum 25(OH)D did not affect the lack of association between change 
in serum 25(OH)D and change in bone turnover markers, nor did analyses of blacks and 
whites separately (Figures 2D-F). Relationships among change variables were not affected 
by month of enrollment nor level of vitamin D3 dose (data not shown).
4. Discussion
This study did not show a positive relationship between serum 25(OH)D levels and 
biochemical markers of bone turnover in healthy pubertal adolescents either at baseline or 
with change over 12 weeks. The lack of a relationship was present in both white and black 
children despite the fact that black adolescents had lower serum 25(OH)D and higher bone 
turnover than whites. These findings corroborate the results of previous cross-sectional 
studies [8, 10] and intervention studies in adolescents using lower doses of oral vitamin D 
[11-13, 15] which found no relationship between serum 25(OH)D and bone turnover. Our 
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study extends these reports by using a larger sample of healthy boys and girls, and showing 
that perturbing baseline serum 25(OH)D through a wide range from zero to 60 ng/ml using 
daily oral vitamin D3 supplementation did not change bone turnover.
The lack of relationship between serum 25(OH)D and bone turnover, and additionally the 
lack of relationship between change in serum 25(OH)D and change in bone turnover 
following 12 weeks of vitamin D supplementation indicates that at baseline these 
adolescents were within the range of serum 25(OH)D required for healthy bone turnover. 
This contrasts with findings in classically defined vitamin D deficiency (serum 25(OH)D < 
10 ng/mL) that produces rickets with increased bone turnover, and which responds to 
vitamin D treatment with a reduction in bone turnover [16]. In a study of Chinese girls [9] 
where a third of the participants had serum 25(OH)D in the deficient range, girls categorized 
as vitamin D deficient (< 10 ng/mL) had higher BAP than those categorized as insufficient 
(<20 ng/mL and > 10 ng/mL) or sufficient (>20 ng/mL), but there were no differences 
between those categorized as insufficient and sufficient. In the present study, median serum 
25(OH)D was 27.6 ng/mL, which is well above the deficiency level of 10 ng/mL, but also 
above the insufficiency level of 20 ng/mL defined by the Institute of Medicine [17]. None of 
the participants in this study had a baseline serum 25(OH)D level defined as deficient. 
Therefore, a limitation of the present study is that it cannot exclude either an association 
between serum 25(OH)D and bone turnover or an effect of improving serum 25(OH)D 
through vitamin D supplementation on bone turnover in children with deficient baseline 
serum 25(OH)D.
Race did not affect the results of this study, despite the finding that blacks had lower serum 
25(OH)D and higher OC compared with whites. Neither adjusting for race in the 
multivariate analyses nor repeating the analyses in whites and blacks separately revealed 
that the lack of relationship between serum 25(OH)D and bone turnover might be race-
dependent.
There were several strengths of this study including the relatively large sample of black and 
white boys and girls from northern and southern U.S. latitudes where each race and sex from 
both latitudes were equally represented. The participants in this study were studied over 
winter months to limit confounding by seasonal sun exposure causing dermal vitamin D 
production, and to ensure that vitamin D supplements would have the greatest effect on low 
serum 25(OH)D. In addition, separate analyses by month of enrollment did not suggest any 
seasonal effect on the relationship between serum 25(OH)D and bone turnover markers in 
this study. The study occurred over 12 weeks, which is sufficient time to observe effects of 
vitamin D on bone turnover [18]. Bone turnover in this study was measured by three 
biochemical markers of bone turnover, which we have shown to be reliable markers of bone 
turnover measured by skeletal calcium retention during calcium balance studies in 
adolescents [19]. The large range of vitamin D doses in this study, extending up to the 
Tolerable Upper Intake Level [17] of 4000 IU/d, produced a wide range of change in serum 
25(OH)D over the 12-week study, which allowed us to investigate the relationship between 
change in 25(OH)D and change in bone turnover. Our study sample represents a relatively 
narrow range of sexual maturity, minimizing confounding from sexual maturation, but does 
limit the results from being generalized to all of childhood. Furthermore, analysis of the data 
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using sexual maturation stage as a covariate did not affect the results. However, self-staging 
of sexual maturation and as use of sexual maturation stage as only a screening measure are 
limitations of the study.
Our sample size was similar to that in the aforementioned Chinese girls study [9] including 
vitamin D deficient girls, which showed a relationship between serum 25(OH)D status and 
bone turnover. Therefore, we were likely adequately powered to detect a relationship. In 
addition, the weakness (R2 ranging from 0.00 to 0.03) of the non-significant relationships 
between serum 25(OH)D and bone turnover markers indicates that even if our sample size 
were larger to produce significant results, these relationships would be of little clinical 
relevance.
5. Conclusions
The results of this study indicate that serum 25(OH)D ranging from 10 to 46 ng/mL during 
winter appears to be sufficient in healthy black and white adolescents for bone turnover, and 
increasing serum 25(OH)D does not affect bone turnover in these children. Our results 
suggest that there is no apparent benefit of increasing serum 25(OH)D for bone turnover in 
children when a winter baseline serum 25(OH)D is above the deficiency level of 10 ng/mL.
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Highlights (3-5 bullet points, max 20 words per point)
• In healthy black and white pubertal children, bone turnover markers are not 
associated with serum 25(OH)D;
• increasing serum 25(OH)D does not affect bone turnover markers;
and serum 25(OH)D ranging from 10-46 ng/mL is sufficient for normal bone 
turnover
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Figure 1. Distribution of serum 25OHD (A) at baseline, (B) 12 weeks, and (C) as change (Δ) from 
baseline to 12 weeks
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Figure 2. 
The relationship between serum 25OHD and (A) serum BAP at baseline, (B) serum OC at 
baseline, and (C) urine NTX at baseline, and the relationship between change in serum 
25OHD after 12 weeks of vitamin D supplementation versus (D) change in serum BAP, (E) 
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change in serum OC, and (F) change in urine NTX. Blacks are represented by filled circles 
and solid lines and white are represented by open circles and dashed lines.
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